Abbott India Ltd
NSE:ABBOTINDIA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
22 452.55
30 195.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Abbott India Ltd
Income from Continuing Operations
Abbott India Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Abbott India Ltd
NSE:ABBOTINDIA
|
Income from Continuing Operations
₹12B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Income from Continuing Operations
₹54.3B
|
CAGR 3-Years
40%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Income from Continuing Operations
₹44.9B
|
CAGR 3-Years
20%
|
CAGR 5-Years
22%
|
CAGR 10-Years
14%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Income from Continuing Operations
₹111.4B
|
CAGR 3-Years
21%
|
CAGR 5-Years
18%
|
CAGR 10-Years
5%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Income from Continuing Operations
₹18B
|
CAGR 3-Years
12%
|
CAGR 5-Years
27%
|
CAGR 10-Years
8%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Income from Continuing Operations
₹19.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Abbott India Ltd
Glance View
Abbott India Ltd., a subsidiary of the global healthcare conglomerate Abbott Laboratories, operates as a key player in India’s pharmaceutical landscape. Nestled in the vibrant, ever-evolving Indian market, Abbott India has carved a niche for itself with a strategic focus on both innovation and localization. Its operations span the development, manufacture, and sale of a wide array of pharmaceutical products. By leveraging Abbott's global expertise and its deep understanding of local market dynamics, the company designs solutions catered to the unique health challenges faced by Indian consumers. Their product portfolio includes a diverse range of proprietary medicines, nutrition products, diagnostics, and branded generics, which address therapeutic areas like cardiology, women's health, gastroenterology, and metabolic disorders. Abbott India’s revenue engine primarily hinges on its extensive distribution networks and its substantial investments in research and development aimed at optimizing treatment paradigms. The company employs a customer-centric approach, working closely with healthcare professionals to ensure the accessibility of its medications across the country. By aligning its operations with the latest trends in healthcare needs and regulatory requirements, Abbott India ensures it remains at the forefront of serving its consumers efficiently. Its commitment to quality and continuous product improvement not only strengthens its market position but also fuels its growth trajectory in the Indian pharmaceutical sector, making it a formidable entity poised for sustained success in a dynamic industry.
See Also
What is Abbott India Ltd's Income from Continuing Operations?
Income from Continuing Operations
12B
INR
Based on the financial report for Mar 31, 2024, Abbott India Ltd's Income from Continuing Operations amounts to 12B INR.
What is Abbott India Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
22%
Over the last year, the Income from Continuing Operations growth was 27%. The average annual Income from Continuing Operations growth rates for Abbott India Ltd have been 20% over the past three years , 22% over the past five years .
You don't have any saved screeners yet
